GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a potent, selective inhibitor of NADPH oxidase isoforms Nox1 and Nox4, with Ki values of 140 nM and 110 nM, respectively. It suppresses reactive oxygen species (ROS) generation, modulating key disease-related pathways such as Akt/mTOR and NF-κB (https://doi.org/10.1126/sciadv.adx6587). GKT137831 demonstrates efficacy in vitro by inhibiting hypoxia-induced H₂O₂ release and cell proliferation, and in vivo by attenuating pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis in mouse models. The compound is recommended for use at 0.1–20 μM concentrations, with robust solubility in DMSO and moderate solubility in ethanol. APExBIO provides GKT137831 (B4763) as a validated research tool for oxidative stress and redox biology (product page).

Biological Rationale

Reactive oxygen species (ROS) are central mediators in cellular signaling and damage. NADPH oxidases, particularly Nox1 and Nox4, are specialized enzymes that generate ROS in response to physiological and pathological stimuli. Excessive ROS contributes to inflammation, fibrosis, vascular remodeling, and metabolic disorders. Selective inhibition of Nox1 and Nox4 allows targeted modulation of ROS without disrupting host defense mechanisms mediated by other Nox isoforms. This strategy addresses unmet needs in models of chronic hypoxia, tissue fibrosis, and cardiovascular complications of diabetes (Yang et al., 2025).

Mechanism of Action of GKT137831

GKT137831 is a small molecule that selectively inhibits Nox1 and Nox4 NADPH oxidases. The inhibitory constants are 140 nM for Nox1 and 110 nM for Nox4. By blocking these enzymes, GKT137831 reduces the formation of superoxide and hydrogen peroxide, major forms of ROS. This leads to decreased activation of redox-sensitive signaling cascades, including:

• Akt/mTOR pathway: Reduced ROS suppresses Akt phosphorylation and downstream mTOR signaling, affecting cell growth and survival.
• NF-κB pathway: Attenuation of ROS inhibits NF-κB activation, resulting in lower expression of pro-inflammatory genes.
• Regulation of TGF-β1 and PPARγ: GKT137831 modulates the expression of these key factors, impacting fibrosis and metabolic regulation.

In vitro, GKT137831 inhibits hypoxia-induced H₂O₂ release and proliferation in human pulmonary artery endothelial and smooth muscle cells. In vivo, oral dosing at 30–60 mg/kg/day reduces pathological remodeling and fibrosis in mouse models (Yang et al., 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 (Ki = 140 nM) and Nox4 (Ki = 110 nM) in enzymatic assays (APExBIO).
• Reduces hypoxia-induced hydrogen peroxide release in HPAECs and HPASMCs cultures, observed after 24-hour incubation at 1–10 μM (Table 1, Yang et al., 2025).
• Suppresses proliferation of vascular cells under hypoxic conditions in vitro (Figure 2, Yang et al., 2025).
• Downregulates TGF-β1 and upregulates PPARγ expression in treated cell models (Yang et al., 2025).
• Oral administration (30–60 mg/kg/day) attenuates pulmonary vascular remodeling and right ventricular hypertrophy in chronic hypoxia mouse models (Yang et al., 2025).
• Reduces liver fibrosis and diabetes-accelerated atherosclerosis in vivo (section 4.2, Yang et al., 2025).
• Soluble at ≥39.5 mg/mL in DMSO and ≥2.96 mg/mL in ethanol with warming/sonication (APExBIO).

This article expands upon recent workflow-focused reviews (see detailed troubleshooting guide) by emphasizing verifiable efficacy data and clinical translation potential.

Unlike previous summaries (mechanistic insights), this article integrates benchmarks and clarifies solubility/storage parameters for direct protocol implementation.

Applications, Limits & Misconceptions

GKT137831 is validated for:

• Oxidative stress research in models of chronic hypoxia, fibrosis, and vascular remodeling.
• Studying the role of Nox1/Nox4 in metabolic diseases, including diabetes-accelerated atherosclerosis.
• Dissecting redox regulation of Akt/mTOR and NF-κB signaling pathways.

GKT137831 does not inhibit other Nox isoforms (e.g., Nox2, Nox5) at relevant concentrations. It is not intended for use as a general antioxidant. Clinical translation is under investigation, but its primary use remains preclinical and mechanistic studies.

Common Pitfalls or Misconceptions

• Non-selectivity: GKT137831 is not a pan-NADPH oxidase inhibitor; it is selective for Nox1 and Nox4.
• Solubility limitations: The compound is insoluble in water and requires DMSO or ethanol (with warming/sonication) for stock preparation.
• Storage: Long-term storage of stock solutions is discouraged; recommended storage is at -20°C as a solid.
• Concentration range: Exceeding recommended working concentrations (0.1–20 μM) may introduce off-target effects.
• In vivo translation: Efficacy in animal models does not guarantee identical outcomes in humans; clinical validation is ongoing.

Workflow Integration & Parameters

For experimental reproducibility, adhere to the following parameters:

• Stock preparation: Dissolve at ≥39.5 mg/mL in DMSO or ≥2.96 mg/mL in ethanol (with warming and sonication).
• Working concentration: Use 0.1–20 μM in cell-based assays; optimal incubation time is 24 hours.
• Animal dosing: 30–60 mg/kg/day by oral gavage in mouse models.
• Storage: Store powder at -20°C; do not store solutions long-term.
• Controls: Include vehicle and positive controls for ROS measurement and signaling pathway analysis.

For troubleshooting and advanced protocol design, see the scenario-based workflows guide, which this article extends by providing explicit solubility and dosing recommendations.

Conclusion & Outlook

GKT137831 from APExBIO is a benchmark selective Nox1/Nox4 inhibitor for oxidative stress research. Its well-defined mechanism, validated efficacy, and established workflow parameters make it an indispensable tool in redox biology and disease modeling. Ongoing clinical studies will further define its translational impact on fibrosis, vascular remodeling, and metabolic disease treatment. For up-to-date product specifications and ordering, refer to the GKT137831 product page.